Biologics/Update·FDA Vaccines, Blood & Biologics

Roster of the Vaccines and Related Biological Products Advisory Committee

LowPublished May 19, 2026· AI-analyzed May 19, 2026View original FDA source

AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.

What happened

The FDA released an updated membership roster for the Vaccines and Related Biological Products Advisory Committee (VRBPAC).

Who it affects

Vaccine manufacturers, biologic product sponsors, and regulatory strategy teams preparing for upcoming advisory committee meetings.

Why it matters

Maintaining current knowledge of advisory committee composition is essential for sponsors anticipating product reviews. Changes in membership can influence the committee's collective expertise and the technical feedback provided during the vaccine and biologic approval process. This roster update likely reflects routine turnover or administrative adjustments within the committee.

Practical takeaway

Regulatory and advocacy teams should review the updated roster to identify the expertise and professional backgrounds of current committee members. Use this information to tailor technical presentations and briefing documents for future VRBPAC meetings.

FDA source material

This is the Roster of the Vaccines and Related Biological Products Advisory Committee

Open in openFDA / FDA.gov

AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.

Roster of the Vaccines and Related Biological Products Advisory Committee

More from Biologics